無料セミナー : 2019年11月19日『手術用ロボット:外科医療におけるトランスフォーメーション』 BIS Research共同開催

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Digital Landscape:乾癬性関節炎(PsA)

Digital Landscape: Psoriatic Arthritis

発行 GlobalData 商品コード 692904
出版日 ページ情報 英文 150 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.25円で換算しております。
Back to Top
Digital Landscape:乾癬性関節炎(PsA) Digital Landscape: Psoriatic Arthritis
出版日: 2018年08月31日 ページ情報: 英文 150 Pages
概要

当レポートでは、米国およびEUCAN諸国(EU5カ国・カナダ)の製薬企業がデジタル環境(ブランドウェブサイト、非ブランド/疾患啓発ウェブサイト、モバイルアプリ、ソーシャルメディア)で乾癬性関節炎患者および医療従事者を対象に展開している取り組みについて詳細に調査し、主要企業の動向の比較、ウェブサイトアクセス数やアプリダウンロード数などのデータ分析、新たなキャンペーン活動の機会の特定、デジタルヘルスを形作るトレンドの評価、患者および医師のオンライン利用実態などについてまとめています。

対象企業

AbbVie、Novartis、Celgene、Janssen、Amgen、MSD、Merck、UCB、BMS、Pfizer、Eli Lilly、Sandoz、Mylan

目次

  • エグゼクティブサマリー
  • 近年の動向
  • 情勢と分析
  • 米国:乾癬性関節炎患者を対象とした取り組み
  • 米国:医療従事者を対象とした取り組み
  • EUCAN諸国:乾癬性関節炎患者を対象とした取り組み
  • EUCAN諸国:医療従事者を対象とした取り組み
  • 調査手法
目次
Product Code: GDHC040SP

"Digital Landscape: Psoriatic Arthritis", analyzes digital activities undertaken by pharma in support of therapies for active psoriatic arthritis (PsA)

The report includes digital activities directed towards patients and/or HCPs.

The geographic scope of the report is the United States, EUCAN (Canada and the 5EU countries - UK, Germany, France, Italy & Spain).

Key Highlights

  • US Patients: AbbVie offers the strongest support for PsA patients in the US, with activity across all channels; most activity in 2017 detected in the branded space following license extensions in PsA, and new advertising campaigns seen for Cosentyx and Enbrel in PsA, while Janssen launched a Remicade-branded counter-biosimilar campaign. Opportunity exists for a well-integrated unbranded campaign to support patients, linked to social media and a mobile app.
  • US HCPs: Good branded support available for US HCPs in PsA, but advertising focus is on other indications. A number of brand sites were updated with PsA content in 2017. Unbranded and mobile app landscapes are sparse, and opportunities may exist to develop or sponsor content with trusted non-pharma organizations. Social media activity is restricted to corporate accounts, with examples of HCP-specific accounts seen in other diseases.
  • EUCAN Patients: Good branded support is available for PsA patients in Germany, the UK, and Canada. Unbranded support is strongest from AbbVie, Novartis and Janssen, however no multi-country, local-language campaigns detected. PsA patients have access to a number of mobile apps, but many are branded or are multi-condition. UCB provides the only example of a PsA-specific mobile app in Europe
  • EUCAN HCPs: The EUCAN HCP landscape is underdeveloped, with little activity seen past branded. The unbranded and mobile app landscapes are particularly sparse, and partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.
  • Companies Mentioned: AbbVie, Novartis, Celgene, Janssen, Amgen, MSD / Merck, UCB, BMS, Pfizer, Eli Lilly, Sandoz, Mylan.

Scope

  • This report analyzes digital activities undertaken by pharma in support of therapies for therapies for active psoriatic arthritis (PsA).
  • The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps.
  • The report is based on analysis conducted by a combination of GlobalData's digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction.
  • The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout.
  • This report covers the research period from January - December 2017.

Reasons to buy

  • Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital PsA space, and can assist our pharma clients derive value in a number of ways:
  • Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in PsA
  • Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns
  • Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands
  • Business Development & Licensing: Assess topics and trends shaping digital health in PsA and beyond, and learn about key patient and physician online activities in PsA.

Table of Contents

  • Executive Summary
  • Recent Developments
  • Landscape & Analysis
  • US: Patient-directed Activities
  • US HCP-directed Activities
  • EUCAN Patient-directed Activities
  • EUCAN HCP-directed Activities
  • Methodology
Back to Top